Skylark Therapeutics

Cell and Gene
Share

Skylark Therapeutics is developing a unique gene silencing platform for the creation of programmable, allogeneic cell therapies. Skylark's differentiated technology allows generation of iPSC-derived products with improved efficacy, safety and accessibility, solving many of the limitations with existing approaches.

Skylark technology facilitates cell therapies which are both programmable and adaptive – engineering novel functionality which responds to both intra- and extra- cellular environmental cues. These next-generation products are able to deliver directed, responsive activities ensuring preferable on- and off-target profiles.   

Our cellular engineering capabilities are supported by our proprietary computational and screening platforms, allowing us to rapidly identify preferred genetic modifications and associated phenotypic outputs through in vitro models.

Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.

Learn more

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.